We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Molecular Prognostic Biomarker Found for CNS Lymphoma

By LabMedica International staff writers
Posted on 24 Jan 2019
Print article
Image: The Affymetrix Genechip 3000 microarray scanner and autoloader fluidics station 450 (Photo courtesy of New-life Scientific).
Image: The Affymetrix Genechip 3000 microarray scanner and autoloader fluidics station 450 (Photo courtesy of New-life Scientific).
Primary central nervous system lymphoma (PCNSL), a rare subgroup of diffuse large B-cell lymphoma (DLBCL) arising in the central nervous system (CNS), is an aggressive malignant variant of nodal non-Hodgkin lymphoma (NHL). PCNSLs account for 3% of all primary CNS tumors and 1% of NHLs in adults.

MicroRNAs (miRNAs) are small noncoding regulatory RNAs consisting of approximately 20-mer nucleotides, that inhibit gene function through suppression of translation of target genes. Dysregulation of miRNA expression and RNA interference (RNAi) mechanism are related to tumor malignancy in chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Scientists at Kyoto Prefectural University of Medicine (Kyoto, Japan) and their colleagues deciphered the miRNA signature through analysis between the expression patterns of miRNAs and their correlation to the prognosis in 27 PCNSL specimens. They first selected 16 miRNA candidates from the 847 miRNAs detected using microarray technique. Then based on principal component analysis (PCA) after Random forest analysis and clustering analysis, they determined that miR-181b, miR-30d, and miR-93 constituted a miRNA signature in PCNSL.

Total RNA was extracted from approximately 100 mg of each tumor tissue and the quality of the extracted RNA was verified with a Bioanalyzer System using RNA Pico Chips. The RNA was amplified twice and used for hybridization with Affymetrix GeneChip miRNA Array, comprising of 30,424 probes. After hybridization, the array chips for target detection were processed, washed, and stained using the Fluidics Station 450. The High-Resolution Microarray Scanner 3000 was used for scanning the signal, and GCOS Workstation Version 1.3 was employed for image-quality analysis.

The team considered the prognostic clues provided by the 16-miRNA gene set, and by a subset of three quantitative PCR-validated miRNAs found by Random forest analysis and clustering analyses: miR-30d, miR-93, and miR-181b. The expression profiles for miRNAs from both signatures could successfully separate PCNSL patients with poor or more favorable overall survival rates. These miRNAs have been implicated in processes ranging from new blood vessel formation to cell migration, proliferation, and immune function, the team noted, and were highly expressed in almost half the PCNSLs tested. The study was published on January 7, 2019, in the journal Public Library of Science ONE.

Related Links:
Kyoto Prefectural University of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.